Mounjaro (tirzepatide) is dosed once weekly by subcutaneous injection and is FDA-labeled only for type 2 diabetes — not for chronic weight management (that label belongs to Zepbound, which is the same molecule). The 6-dose ladder is identical to Zepbound, but the decision to step up is driven by glycemic control rather than weight-loss response. Use this page as a pocket reference; for deeper context, see the links at the bottom.
Dose ladder (subcutaneous, once weekly)
| Step | Minimum weeks at dose | Dose | Notes |
|---|---|---|---|
| 1 | 4 weeks | 2.5 mg | Starting dose. Not a treatment dose for glycemic control — only to acclimate the gut. |
| 2 | 4+ weeks | 5 mg | First therapeutic dose. Many patients meet A1C goal here. |
| 3 | 4+ weeks | 7.5 mg | Step up only if additional glycemic control is needed. |
| 4 | 4+ weeks | 10 mg | Pediatric ceiling (patients 10–17 years stop here). |
| 5 | 4+ weeks | 12.5 mg | Step up only if A1C still above target. |
| 6 | Maintenance | 15 mg | Adult ceiling. Same dose used in SURPASS-2 (−11.2 kg / 40 wk vs semaglutide). |
Source: DailyMed Mounjaro SPL, SetID d2d7da5d-ad07-4228-955f-cf7e355c8cc0.
When to step up vs. hold
Unlike Zepbound (where escalation is driven by weight-loss response), Mounjaro escalation is anchored to glycemic control. Use these decision rules at each 4-week checkpoint:
| Clinical picture at checkpoint | Action |
|---|---|
| A1C still above goal (typically >7%) after ≥ 4 weeks at current dose, GI symptoms tolerable | Step up to the next dose level. |
| A1C at goal, fasting glucose at target, no troubling GI symptoms | Hold at current dose. There is no benefit to climbing further. |
| Grade 2 GI side effects (nausea, vomiting, or diarrhea that interferes with daily activities) | Hold at the current dose for another 4 weeks; do not advance. |
| Persistent grade 3+ adverse event (severe nausea/vomiting, dehydration, severe abdominal pain) | De-escalate one level or pause therapy and call the prescriber. |
| Frequent hypoglycemia on concurrent insulin or sulfonylurea | Do not step up. Reduce the secretagogue or insulin dose first, then reassess. |
The A1C goal of <7% is the canonical ADA target for most non-pregnant adults with type 2 diabetes; an individualized target (e.g., <6.5% in younger patients with low hypoglycemia risk, or <8% in older adults with limited life expectancy) may apply. Confirm with the prescriber.
Quick facts
- Inject same day each week. Any time of day, with or without food.
- Minimum 4 weeks between escalations. The label does not authorize faster climbs; the schedule limits nausea, vomiting, and dehydration.
- Slower is allowed. Staying 8–12 weeks at a step is fine if A1C is acceptable or GI symptoms persist.
- Insurance PA criteria for Mounjaro typically require documented A1C ≥ 6.5% and prior metformin trial; weight-only requests are usually denied.
- Injection sites: abdomen, thigh, or upper arm. Rotate weekly. Avoid bruised, scarred, or tender skin.
- Storage: refrigerate unused pens at 36–46°F. Once in use, a pen can be kept at room temperature (up to 86°F) for up to 21 days, then discarded.
Missed-dose protocol
From the FDA label: if the missed dose is noticed within 4 days (96 hours) of the scheduled day, administer it as soon as possible. If more than 4 days have passed, skip that dose and resume the regular weekly schedule. The day of the week may be changed as long as the gap between two doses is at least 3 days (72 hours). Do not double up to make up a missed dose. If two or more consecutive doses are missed, contact the prescriber — a re-titration from a lower step may be needed.
Call your doctor if...
- Severe, persistent abdominal pain — especially radiating to the back, with or without vomiting. Possible acute pancreatitis; discontinue Mounjaro promptly.
- Right-upper-quadrant pain, fever, jaundice, or clay-colored stools. Possible gallbladder disease (cholelithiasis was reported more often on tirzepatide than placebo in clinical trials).
- Severe hypoglycemia (confusion, loss of consciousness, seizure) if also taking insulin or a sulfonylurea. The Mounjaro label specifically warns of increased severe-hypoglycemia risk in this combination — the diabetes drug dose typically must be reduced.
- Vomiting that prevents fluid intake for more than 24 hours, dizziness on standing, dark urine, or low urine output. Acute kidney injury from volume depletion has been reported.
- A lump or swelling in the neck, hoarseness, or difficulty swallowing. Boxed warning: thyroid C-cell tumors in rodents; do not use with a personal or family history of medullary thyroid carcinoma or MEN 2.
- Vision changes in patients with type 2 diabetes (transient worsening of diabetic retinopathy has been reported with rapid glycemic improvement).
- Hives, swelling of the face or throat, or trouble breathing. Hypersensitivity and angioedema have been reported — stop Mounjaro and seek emergency care.
What this cheat sheet does not cover
This page is the dosing skeleton for type 2 diabetes. It does not cover the diagnostic workup for diabetic ketoacidosis (which can present atypically in T2D on incretin therapy), the full nuance of pancreatitis evaluation (lipase thresholds, imaging triggers, when to restart), pregnancy and lactation guidance, perioperative management before procedures requiring fasting, the new KwikPen multidose device instructions, or use in patients with prior bariatric surgery. It also does not cover Mounjaro for weight loss, which is off-label here — see Zepbound for the FDA-labeled chronic-weight-management indication of the same molecule.
Related on Weight Loss Rankings
- Mounjaro drug overview — mechanism, SURPASS trial data, pricing, and 2026 label changes.
- GLP-1 Titration Planner — interactive week-by-week dose schedule with calendar export.
- GLP-1 Missed-Dose Guide — the 96-hour rule applied to every GLP-1, with worked examples.
- Top GLP-1 Cardiovascular Studies — SURPASS-CVOT and the macrovascular evidence behind tirzepatide.
- Ozempic vs Mounjaro — the head-to-head verdict for type 2 diabetes patients deciding between semaglutide and tirzepatide.